(S)-2-((1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydro-1H-inden-1-yl)propyl pivalate | 148041-17-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-2-((1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydro-1H-inden-1-yl)propyl pivalate
• 英文别名: (2S)-2-[(1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydro-1H-inden-1-yl]propyl pivalate；(S)-2-((1R,3αR,4S,7αR)-4-hydroxy-7α-methyloctahydro-1H-inden-1-yl)propyl pivalate；[(2S)-2-[(1R,3aR,4S,7aR)-4-hydroxy-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-1-yl]propyl] 2,2-dimethylpropanoate
• CAS: 148041-17-2
• 化学式: C₁₈H₃₂O₃
• 分子量: 296.45
• InChiKey: KKIJMEVZCRQJFP-KAYRBKQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-((1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydro-1H-inden-1-yl)propyl pivalate 在 4-甲基苯磺酸吡啶 重铬酸吡啶 作用下， 以 二氯甲烷 为溶剂， 以94%的产率得到(2S)-2-[(1R,3aR,7aR)-7a-methyl-4-oxooctahydro-1H-inden-1-yl]propyl pivalate
  参考文献：
  名称：

  [EN] VITAMIN D RECEPTOR AGONISTS AND USES THEREOF
  [FR] AGONISTES DU RÉCEPTEUR DE LA VITAMINE D ET UTILISATIONS CORRESPONDANTES

  摘要：

  揭示的是化合物Formula (I)，其中R1、R2、R3、R4、R5、R6、X和a在此处定义，或其药用可接受盐。还揭示了一种包含Formula (I)的化合物或其盐的制药组合物，以及一种治疗受益于调节维生素D受体的疾病的方法，如骨骼疾病、心血管疾病、与肾脏疾病相关的心血管并发症、内皮功能障碍、甲状旁腺功能亢进、低钙血症、免疫障碍、左心室肥厚、增殖性疾病、蛋白尿、肾脏疾病和血栓形成。

  公开号：

  WO2010120698A1
• 作为产物：
  描述：

  (1R,3AR,4S,7AR)-1-[(2S)-1-羟基丙-2-基]-7A-甲基-1,2,3,3A,4,5,6,7-八氢茚-4-醇 、 三甲基乙酸 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 (S)-2-((1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydro-1H-inden-1-yl)propyl pivalate
  参考文献：
  名称：

  Analogues of the Inhoffen–Lythgoe diol with anti-proliferative activity

  摘要：

  The anti-proliferative activity of a series of ester-and amide-linked Inhoffen-Lythgoe side chain analogues is reported. Whereas the Inhoffen-Lythgoe diol was inactive in these studies, a number of aromatic and aliphatic ester-linked side chains demonstrated modest in vitro growth inhibition in two human cancepar cell lines, U87MG (glioblastoma) and HT-29 (colorectal adenocarcinoma). Structureactivity relationship (SAR) studies demonstrated the most active aromatic (13) and aliphatic (25 and 29) substituted analogues were approximately equipotent in U87MG and HT-29 cells. Further evaluation of 13, 25, and 29 indicated these analogues do not activate canonical vitamin D signaling nor antagonize Hedgehog (Hh) signaling. Thus, the cellular mechanism(s) that govern the anti-proliferative activity for this class of truncated vitamin D-based structures appears to be different from classical mechanisms previously identified for these scaffolds. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.054

文献信息

• VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING
  申请人：Von Geldern Thomas W.

  公开号：US20090131379A1

  公开（公告）日：2009-05-21

  The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

  该发明涉及一种维生素D受体激活剂化合物，包括这种化合物的组合物，使用这种化合物和组合物的方法，制备这种化合物的过程，以及在这些过程中获得的中间体。
• Vitamin D Receptor Agonists and Uses Thereof
  申请人：Kawai Megumi

  公开号：US20120115824A1

  公开（公告）日：2012-05-10

  Disclosed is a compound of Formula (I) in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt thereof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.

  本发明公开了一种式（I）的化合物，其中R1、R2、R3、R4、R5、R6、X和a如本文所定义，或其药学上可接受的盐。本发明还公开了一种包括式（I）的化合物或其盐的制药组合物，以及一种治疗需要调节维生素D受体的疾病的方法，例如骨疾病、心血管疾病、与肾脏疾病相关的心血管并发症、内皮功能障碍、甲状旁腺功能亢进、低钙血症、免疫紊乱、左心室肥厚、增生性疾病、蛋白尿、肾脏疾病和血栓形成等疾病。
• Vitamin D receptor activators and methods of making
  申请人：Von Geldern Thomas W.

  公开号：US08377913B2

  公开（公告）日：2013-02-19

  The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

  本发明涉及一种维生素D受体激活剂化合物，包括该化合物的组合物、使用该化合物和组合物的方法、制备该化合物的方法以及在这些过程中获得的中间体。
• VITAMIN D RECEPTOR AGONISTS AND USES THEREOF
  申请人：Vidasym, Inc.

  公开号：EP2419403B1

  公开（公告）日：2016-09-07
• US8377913B2
  申请人：——

  公开号：US8377913B2

  公开（公告）日：2013-02-19